A hype-heavy explainer on retatrutide, the Lilly drug that targets three hormone pathways at once. It doesn't add anything new on trials or approval timing.
Recap by typeshit. Post by Facebook on Facebook.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
AFRO News reports that while GLP-1 drugs help with weight and diabetes, losing weight quickly may also reduce muscle and bone, and doctors are urging patients to take care.
The NHS says it knows some people are getting hold of retatrutide for weight loss and reminds them the trial drug has no license or approval.
Loading…